ArticleFrontiers in immunology2022

PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma.

Yu-Min Zhong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.